Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Heikki Kuusanmäki, Aino-Maija Leppä, Petri Pölönen, Mika Kontro, Olli Dufva, Debashish Deb, Bhagwan Yadav, Oscar Brück, Ashwini Kumar, Hele Everaus, Bjørn T. Gjertsen, Merja Heinäniemi, Kimmo Porkka, Satu Mustjoki, and Caroline A. Heckman

Disclosures: CAH has received research funding from Celgene, Novartis, Oncopeptides, Orion Pharma and Pfizer (unrelated to this project). SM has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb and research funding from Ariad (unrelated to this project). KP has received research funding from Bristol-Myers Squibb, Pfizer, Novartis and Celgene (unrelated to this project).

Contributions: HK and AML designed the study, performed the experiments and wrote the manuscript. PP, MH and AK performed gene expression and pathway analysis studies. MK, OB, BTG and HE collected clinical information and provided samples. OD and MK analyzed the data and performed critical revision of the manuscript. DD performed wet lab experiments. BY calculated the drug sensitivity and combination scores. SM, KP and CAH conceived the study, edited the manuscript and supervised the work. All the authors contributed to the writing and approved the final manuscript.